Canine atopic dermatitis attenuated by mesenchymal stem cells

Abstract

Objective: To evaluate the use of mesenchymal stem cells (MSCs) in the attenuation of canine atopic dermatitis (AD). Materials and methods: Sixteen dogs were selected and divided into three groups, mild, moderate, and severe, according to the Canine Atopic Dermatitis Extent and Severity Index (CADESI-4). They were evaluated for 82 days. The protocol recommended in this experiment was to inject 2 × 10 6 /kg bodyweight of MSC’s in all groups by the intravenous route with intervals of applications of 21 days. The degree of pruritus was evaluated by examining the visual analog scale, the CADESI-4, the histopathology of the skin, hematological and biochemical parameters, the pyogenic effect of MSCs, and the thickness of the epidermis. Results: There was a significant difference in the reduction of epidermal thickness in the moderate and severe groups. Hematological, biochemical, and body temperature parameters remained within normal limits for the species with no side effects Conclusion: MSCs attenuated the clinical signs of AD.

Recent advance in mesenchymal stem cells therapy for atopic dermatitis

“…Their result indicated that most AD symptoms and associated comorbidities in AD dogs were eliminated and/or diminished 6 weeks after the initial treatment 54 . Subsequently, another study reported that the allogenic adipose‐derived MSCs (2 × 10 6 cells/kg) were administrated intravenously into 16 AD dogs every 21 days, and the study results showed that MSC treatment significantly attenuated the clinical signs of AD in dogs without local or systemic adverse reactions observed 18 …”

“…54 Subsequently, another study reported that the allogenic adipose-derived MSCs (2 × 10 6 cells/kg) were administrated intravenously into 16 AD dogs every 21 days, and the study results showed that MSC treatment significantly attenuated the clinical signs of AD in dogs without local or systemic adverse reactions observed. 18 T A B L E 1 Current clinical applications of MSCs-derived from various tissues as a therapeutic option…”

“…Canines AD Adipose-MSCs IV Proliferation of PBMCs is inhibited [53] Canines AD Adipose-MSCs IM Efficacy in several breeds, no adverse reactions reported [54] Canines AD Adipose-MSCs IV Epidermal thickness decreased [18] Canines AD Adipose-MSCs SC Efficacious in alleviating clinical signs [55] Note: NCT is the number assigned to each clinical trial that is registered on ClinicalTrials.gov.…”

“…14 In recent years of studies, MSCs have been shown as a potential alternative therapy for immunological-related diseases like asthma, lupus, and AD. [15][16][17][18] In this paper, we will review the recent advances in the treatment of AD by MSCs and MSCsderived conditional media and exosomes.…”

“…Importantly, MSCs display unique immunosuppressive and immune tolerant features, which make allogeneic MSCs' transplant an ideal cell therapy 14 . In recent years of studies, MSCs have been shown as a potential alternative therapy for immunological‐related diseases like asthma, lupus, and AD 15–18 . In this paper, we will review the recent advances in the treatment of AD by MSCs and MSCs‐derived conditional media and exosomes.…”